JP2015518903A5 - - Google Patents

Download PDF

Info

Publication number
JP2015518903A5
JP2015518903A5 JP2015516256A JP2015516256A JP2015518903A5 JP 2015518903 A5 JP2015518903 A5 JP 2015518903A5 JP 2015516256 A JP2015516256 A JP 2015516256A JP 2015516256 A JP2015516256 A JP 2015516256A JP 2015518903 A5 JP2015518903 A5 JP 2015518903A5
Authority
JP
Japan
Prior art keywords
compound
acceptable salt
pharmaceutically acceptable
optionally substituted
composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2015516256A
Other languages
English (en)
Japanese (ja)
Other versions
JP2015518903A (ja
JP6214643B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2013/044800 external-priority patent/WO2013185084A1/en
Publication of JP2015518903A publication Critical patent/JP2015518903A/ja
Publication of JP2015518903A5 publication Critical patent/JP2015518903A5/ja
Application granted granted Critical
Publication of JP6214643B2 publication Critical patent/JP6214643B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2015516256A 2012-06-08 2013-06-07 ピリミジニルチロシンキナーゼ阻害剤 Expired - Fee Related JP6214643B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261657360P 2012-06-08 2012-06-08
US61/657,360 2012-06-08
PCT/US2013/044800 WO2013185084A1 (en) 2012-06-08 2013-06-07 Pyrimidinyl tyrosine kinase inhibitors

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2017150480A Division JP2017193583A (ja) 2012-06-08 2017-08-03 ピリミジニルチロシンキナーゼ阻害剤

Publications (3)

Publication Number Publication Date
JP2015518903A JP2015518903A (ja) 2015-07-06
JP2015518903A5 true JP2015518903A5 (enExample) 2016-07-28
JP6214643B2 JP6214643B2 (ja) 2017-10-18

Family

ID=49712704

Family Applications (6)

Application Number Title Priority Date Filing Date
JP2015516256A Expired - Fee Related JP6214643B2 (ja) 2012-06-08 2013-06-07 ピリミジニルチロシンキナーゼ阻害剤
JP2017150480A Withdrawn JP2017193583A (ja) 2012-06-08 2017-08-03 ピリミジニルチロシンキナーゼ阻害剤
JP2019017850A Withdrawn JP2019077728A (ja) 2012-06-08 2019-02-04 ピリミジニルチロシンキナーゼ阻害剤
JP2021018128A Pending JP2021073299A (ja) 2012-06-08 2021-02-08 ピリミジニルチロシンキナーゼ阻害剤
JP2021018127A Pending JP2021073298A (ja) 2012-06-08 2021-02-08 ピリミジニルチロシンキナーゼ阻害剤
JP2023004462A Pending JP2023052415A (ja) 2012-06-08 2023-01-16 ピリミジニルチロシンキナーゼ阻害剤

Family Applications After (5)

Application Number Title Priority Date Filing Date
JP2017150480A Withdrawn JP2017193583A (ja) 2012-06-08 2017-08-03 ピリミジニルチロシンキナーゼ阻害剤
JP2019017850A Withdrawn JP2019077728A (ja) 2012-06-08 2019-02-04 ピリミジニルチロシンキナーゼ阻害剤
JP2021018128A Pending JP2021073299A (ja) 2012-06-08 2021-02-08 ピリミジニルチロシンキナーゼ阻害剤
JP2021018127A Pending JP2021073298A (ja) 2012-06-08 2021-02-08 ピリミジニルチロシンキナーゼ阻害剤
JP2023004462A Pending JP2023052415A (ja) 2012-06-08 2023-01-16 ピリミジニルチロシンキナーゼ阻害剤

Country Status (30)

Country Link
US (6) US9394277B2 (enExample)
EP (3) EP3753934A1 (enExample)
JP (6) JP6214643B2 (enExample)
KR (4) KR20200043497A (enExample)
CN (3) CN113549055A (enExample)
AR (1) AR091273A1 (enExample)
AU (5) AU2013271407B2 (enExample)
BR (2) BR112014030655B1 (enExample)
CA (2) CA3108186A1 (enExample)
CY (1) CY1120638T1 (enExample)
DK (1) DK2858499T3 (enExample)
EA (2) EA027823B1 (enExample)
ES (2) ES2684268T3 (enExample)
HR (1) HRP20181294T1 (enExample)
HU (1) HUE039897T2 (enExample)
IL (2) IL235938B (enExample)
IN (1) IN2014DN10576A (enExample)
LT (1) LT2858499T (enExample)
MX (2) MX363672B (enExample)
NZ (1) NZ702715A (enExample)
PH (2) PH12018501463B1 (enExample)
PL (1) PL2858499T3 (enExample)
PT (1) PT2858499T (enExample)
RS (1) RS57978B1 (enExample)
SG (2) SG11201408173WA (enExample)
SI (1) SI2858499T1 (enExample)
SM (1) SMT201800442T1 (enExample)
TW (3) TWI592406B (enExample)
WO (1) WO2013185084A1 (enExample)
ZA (1) ZA201409255B (enExample)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2771822C (en) * 2009-09-04 2020-08-11 Daniel A. Erlanson Bruton's tyrosine kinase inhibitors
WO2012058645A1 (en) 2010-10-29 2012-05-03 Biogen Idec Ma Inc. Heterocyclic tyrosine kinase inhibitors
AR091273A1 (es) * 2012-06-08 2015-01-21 Biogen Idec Inc Inhibidores de pirimidinil tirosina quinasa
EP2858500A4 (en) 2012-06-08 2016-04-06 Biogen Ma Inc BRUTON TYROSINE KINASE HEMMER
HRP20181109T1 (hr) * 2013-12-11 2018-11-02 Biogen Ma Inc. Spojevi biarila korisni za liječenje ljudskih bolesti u onkologiji, neurologiji i imunologiji
WO2015151006A1 (en) 2014-03-29 2015-10-08 Lupin Limited Substituted purine compounds as btk inhibitors
WO2015170266A1 (en) 2014-05-07 2015-11-12 Lupin Limited Substituted pyrimidine compounds as btk inhibitors
AR102426A1 (es) * 2014-10-24 2017-03-01 Bristol Myers Squibb Co Compuestos de indolcarboxamida como inhibidores de btk
SG11201900515PA (en) * 2016-07-21 2019-02-27 Biogen Ma Inc Succinate forms and compositions of bruton's tyrosine kinase inhibitors
EP3789040A4 (en) 2018-04-27 2022-03-09 ONO Pharmaceutical Co., Ltd. PREVENTIVE AND/OR THERAPEUTIC AGENT FOR AUTOIMMUNE DISEASES WITH A COMPOUND WITH BTK INHIBITING ACTIVITY AS AN INGREDIENT
CA3224985C (en) 2018-07-31 2025-11-18 Loxo Oncology, Inc. SPRAY-DRIED DISPERSIONS, FORMULATIONS AND POLYMORPHIES OF (S)-5-AMINO-3-(4-((5-FLUORO-2-METHOXYBENZAMIDO)METHYL)PHENYL)(1,1,1-TRIFLUOROPROPANE-2-YL)-1H-PYRAZOLE-4-CARBOXAMIDE
EP3942045A1 (en) 2019-03-21 2022-01-26 Onxeo A dbait molecule in combination with kinase inhibitor for the treatment of cancer
EP4054579A1 (en) 2019-11-08 2022-09-14 Institut National de la Santé et de la Recherche Médicale (INSERM) Methods for the treatment of cancers that have acquired resistance to kinase inhibitors
WO2021148581A1 (en) 2020-01-22 2021-07-29 Onxeo Novel dbait molecule and its use
US20240100172A1 (en) 2020-12-21 2024-03-28 Hangzhou Jijing Pharmaceutical Technology Limited Methods and compounds for targeted autophagy
WO2022212893A1 (en) 2021-04-02 2022-10-06 Biogen Ma Inc. Combination treatment methods of multiple sclerosis
US20260083848A1 (en) 2021-11-03 2026-03-26 Viracta Therapeutics, Inc. Combination of car t-cell therapy with btk inhibitors and methods of use thereof
WO2023081709A1 (en) 2021-11-03 2023-05-11 Viracta Therapeutics, Inc. Vecabrutinib for the treatment of graft-versus-host disease
KR20240157639A (ko) 2021-12-14 2024-11-01 크로스파이어 온콜로지 홀딩 비.브이. 거대고리 btk 억제제
WO2024246287A1 (en) 2023-06-02 2024-12-05 Crossfire Oncology Holding B.V. Medical use of a macrocyclic reversible btk inhibitor
WO2024245578A1 (en) 2023-06-02 2024-12-05 Netherlands Translational Research Center Holding B.V. Therapeutic combinations of an irreversible btk inhibitor and a macrocyclic reversible btk inhibitor
WO2024245577A1 (en) 2023-06-02 2024-12-05 Netherlands Translational Research Center Holding B.V. Therapeutic combinations of an irreversible btk inhibitor and a reversible btk inhibitor
WO2024256568A1 (en) 2023-06-13 2024-12-19 Crossfire Oncology Holding B.V. Salt and crystal forms of a macrocyclic btk inhibitor
WO2024256574A1 (en) 2023-06-13 2024-12-19 Crossfire Oncology Holding B.V. Process for preparing macrocyclic btk inhibitors

Family Cites Families (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1624A (en) * 1840-06-10 Cooking-stove
US4528138A (en) 1984-06-20 1985-07-09 E. R. Squibb & Sons, Inc. 16-Keto-17-substituted thia-17-alkyl(or alkenyl or alkynyl) androstenes
US4911920A (en) 1986-07-30 1990-03-27 Alcon Laboratories, Inc. Sustained release, comfort formulation for glaucoma therapy
FR2588189B1 (fr) 1985-10-03 1988-12-02 Merck Sharp & Dohme Composition pharmaceutique de type a transition de phase liquide-gel
DK0495421T3 (da) 1991-01-15 1996-12-09 Alcon Lab Inc Anvendelse af carragenaner i topiske ophthalmiske sammensætninger
US5212162A (en) 1991-03-27 1993-05-18 Alcon Laboratories, Inc. Use of combinations gelling polysaccharides and finely divided drug carrier substrates in topical ophthalmic compositions
US6309853B1 (en) 1994-08-17 2001-10-30 The Rockfeller University Modulators of body weight, corresponding nucleic acids and proteins, and diagnostic and therapeutic uses thereof
PA8474101A1 (es) 1998-06-19 2000-09-29 Pfizer Prod Inc Compuestos de pirrolo [2,3-d] pirimidina
US6919178B2 (en) 2000-11-21 2005-07-19 Sunesis Pharmaceuticals, Inc. Extended tethering approach for rapid identification of ligands
CN1481377A (zh) 2000-03-17 2004-03-10 ����˹�ж�-����˹˹����ҩƷ��˾ 作为基质金属蛋白酶和TNF-α的抑制剂的环β-氨基酸衍生物
MY137020A (en) 2000-04-27 2008-12-31 Abbott Lab Diazabicyclic central nervous system active agents
EA006153B1 (ru) 2000-06-26 2005-10-27 Пфайзер Продактс Инк. СОЕДИНЕНИЯ ПИРРОЛО[2,3-d]ПИРИМИДИНА В КАЧЕСТВЕ ИММУНОДЕПРЕССАНТОВ
PE20020507A1 (es) * 2000-10-17 2002-06-25 Schering Corp Compuestos no-imidazoles como antagonistas del receptor histamina h3
AU2002363236A1 (en) * 2001-10-30 2003-05-12 Millennium Pharmaceuticals, Inc. Compounds, pharmaceutical compositions and methods of use therefor
CA2464934A1 (en) 2001-10-31 2003-05-08 Bayer Healthcare Ag Pyrimido [4,5-b] indole derivatives
CN102558155A (zh) 2003-01-14 2012-07-11 阿伦纳药品公司 作为代谢调节剂的芳基和杂芳基衍生物及其所涉及的疾病如糖尿病和高血糖症的预防和治疗
ES2344007T3 (es) 2003-10-14 2010-08-16 The Arizona Board Of Regents On Behalf Of The University Of Arizona Inhibidores proteina quinasa.
WO2006073419A2 (en) * 2004-04-01 2006-07-13 Gang Zheng Lipoprotein nanoplatforms
WO2005117909A2 (en) 2004-04-23 2005-12-15 Exelixis, Inc. Kinase modulators and methods of use
FR2870541B1 (fr) 2004-05-18 2006-07-14 Proskelia Sas Derives de pyrimidines antigonistes du recepteur de la vitronectine
AR050865A1 (es) 2004-09-09 2006-11-29 Sanofi Aventis Derivados de 2- morfolino-4-pirimidona
ES2354824T3 (es) * 2004-11-04 2011-03-18 Vertex Pharmaceuticals, Inc. Pirazolo[1,5-a]pirimidinas útiles como inhibidores de proteínas cinasas.
WO2006060461A1 (en) 2004-12-03 2006-06-08 Schering Corporation Substituted piperazines as cb1 antagonists
US7994172B2 (en) 2004-12-28 2011-08-09 Exelixis, Inc. [1H-pyrazolo[3, 4-D]pyrimidin-4-yl]-piperidine or -piperazine compounds as serine-theoronine kinase modulators (P70s6k, Atk1 and Atk2) for the treatment of immunological, inflammatory and proliferative diseases
US7880002B2 (en) 2004-12-29 2011-02-01 Millennium Pharmaceuticals, Inc. Substituted piperazinyl-pyrrolidine compounds useful as chemokine receptor antagonists
WO2006091450A1 (en) * 2005-02-18 2006-08-31 Lexicon Genetics Incorporated 4-piperidin-1-yl-7h-pyrrolo[2,3-d]pyrimidine compounds
US20060281700A1 (en) 2005-06-10 2006-12-14 Baumann Christian A Synergistic modulation of flt3 kinase using aminopyrimidines kinase modulators
US20060281764A1 (en) 2005-06-10 2006-12-14 Gaul Michael D Aminopyrimidines as kinase modulators
TW200740779A (en) 2005-07-22 2007-11-01 Mitsubishi Pharma Corp Intermediate compound for synthesizing pharmaceutical agent and production method thereof
US7528143B2 (en) 2005-11-01 2009-05-05 Targegen, Inc. Bi-aryl meta-pyrimidine inhibitors of kinases
BRPI0620386A2 (pt) * 2005-12-21 2011-12-20 Schering Corp composição compreendendo a combinação de um antagonista de h3/agonista inverso e um supressor de apetite e uso da referida composição
US20080076924A1 (en) 2006-06-30 2008-03-27 Patrick Betschmann Piperazines as P2X7 antagonists
WO2008012635A2 (en) 2006-07-26 2008-01-31 Pfizer Products Inc. Amine derivatives useful as anticancer agents
US20090325948A1 (en) 2006-07-26 2009-12-31 Timothy Brian Hurley Inhibitors of undecaprenyl pyrophosphate synthase
JP2010502751A (ja) * 2006-09-11 2010-01-28 シージーアイ ファーマシューティカルズ,インコーポレイティド キナーゼ阻害物質、およびキナーゼ阻害物質の使用および同定方法
PL2526933T3 (pl) 2006-09-22 2015-08-31 Pharmacyclics Llc Inhibitory kinazy tyrozynowej Brutona
AU2009243094B2 (en) 2006-11-06 2015-02-12 Massachusetts Institute Of Technology Immunomodulating compositions and methods of use thereof
CN101674831A (zh) * 2007-03-02 2010-03-17 先灵公司 用于治疗糖尿病或疼痛的哌啶基哌啶和哌嗪基哌啶
JP2010522241A (ja) 2007-03-21 2010-07-01 ブリストル−マイヤーズ スクイブ カンパニー 増殖性疾患、アレルギー性疾患、自己免疫疾患または炎症性疾患として有用な縮合ヘテロ環化合物
WO2008144253A1 (en) 2007-05-14 2008-11-27 Irm Llc Protein kinase inhibitors and methods for using thereof
RU2469036C2 (ru) 2007-06-01 2012-12-10 ГЛАКСОСМИТКЛАЙН ЭлЭлСи Имидазопиридиновые ингибиторы киназ
DK2242749T3 (da) 2008-02-05 2013-06-17 Hoffmann La Roche Nye pyridinoner og pyridazinoner
CA2730930C (en) 2008-07-16 2015-01-13 Pharmacyclics, Inc. Inhibitors of bruton's tyrosine kinase for the treatment of solid tumors
WO2010068788A1 (en) * 2008-12-10 2010-06-17 Cgi Pharmaceuticals, Inc. Heterocyclic amides as btk inhibitors
ES2443948T3 (es) * 2008-12-19 2014-02-21 Bristol-Myers Squibb Company Compuestos de carbazol carboxamida útiles como inhibidores de quinasas
CA2748181C (en) * 2009-01-06 2019-07-16 Nathanael S. Gray Pyrimido-diazepinone kinase scaffold compounds and methods of treating disorders
ES2565952T3 (es) 2009-05-25 2016-04-07 Sandoz Ag Método para la producción de ceftobiprol medocaril
WO2011029043A1 (en) 2009-09-04 2011-03-10 Biogen Idec Ma Inc. Heteroaryl btk inhibitors
CA2771822C (en) 2009-09-04 2020-08-11 Daniel A. Erlanson Bruton's tyrosine kinase inhibitors
US8685880B2 (en) * 2010-06-30 2014-04-01 Chevron U.S.A. Inc. On-site drying of aqueous salt for ionic liquid make-up
WO2012058645A1 (en) 2010-10-29 2012-05-03 Biogen Idec Ma Inc. Heterocyclic tyrosine kinase inhibitors
AR091273A1 (es) * 2012-06-08 2015-01-21 Biogen Idec Inc Inhibidores de pirimidinil tirosina quinasa
EP2858500A4 (en) 2012-06-08 2016-04-06 Biogen Ma Inc BRUTON TYROSINE KINASE HEMMER
HRP20181109T1 (hr) 2013-12-11 2018-11-02 Biogen Ma Inc. Spojevi biarila korisni za liječenje ljudskih bolesti u onkologiji, neurologiji i imunologiji
US10280169B2 (en) 2013-12-11 2019-05-07 Biogen Ma Inc. Biaryl bruton's tyrosine kinase inhibitors
WO2016054627A1 (en) 2014-10-03 2016-04-07 Ohio State Innovation Foundation Biomarkers of bruton tyrosine kinase inhibitor resistance
SG11201900515PA (en) * 2016-07-21 2019-02-27 Biogen Ma Inc Succinate forms and compositions of bruton's tyrosine kinase inhibitors

Similar Documents

Publication Publication Date Title
JP2018520455A5 (enExample)
CY1124222T1 (el) Ενωσεις πυριδινονης-πυριδινυλιου υποκατεστημενες με μεθυλο/φθορο-πυριδινυλο-μεθοξυ και ενωσεις πυριδινονης-πυριδινυλιου υποκατεστημενες με φθορο-πυριδινυλο-μεθοξυ
JP2016536364A5 (enExample)
MX2022005399A (es) Compuestos.
JP2017536369A5 (enExample)
JP2016536363A5 (enExample)
JP2015535277A5 (enExample)
JP2015181191A5 (enExample)
JP2013147496A5 (ja) 有機金属錯体
RU2017120274A (ru) Гетероарильные соединения в качестве ингибиторов irak и их применения
JP2010535722A5 (enExample)
JP2017524733A5 (enExample)
EA201600373A1 (ru) ПИРРОЛО[2,3-d]ПИРИМИДИНИЛ-, ПИРРОЛО[2,3-b]ПИРАЗИНИЛ- И ПИРРОЛО[2,3-d]ПИРИДИНИЛАКРИЛАМИДЫ
JP2019081762A5 (enExample)
JP2016534134A5 (enExample)
JP2019519587A5 (enExample)
MX2021001583A (es) Formas sólidas cristalinas de n-{4-[(6,7-dimetoxiquinolin-4-il)oxi ] fenil}-n'-(4-fluorofenil)ciclopropan-1,1-dicarboxamida, procesos para elaboración y métodos de uso.
JP2017518323A5 (enExample)
JP2017052761A5 (enExample)
JP2017071790A5 (enExample)
JP2015091935A5 (enExample)
JP2019516739A5 (enExample)
JP2017515919A5 (enExample)
JP2014526533A5 (enExample)
JP2013147490A5 (ja) イリジウム錯体